Vanguard Asset Management
PCVX icon

Vanguard Asset Management’s Vaxcyte PCVX Stock Holding History

Vanguard Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Buy
115,020
+5,777
+5% +$314K ﹤0.01% 908
2026
Q1 		$6.35M Buy
+109,243
New +$5.93M 0.01% 829

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Asset Management's PCVX Position: Q2 2026 in Review

Vanguard Asset Management increased its Vaxcyte (PCVX) stake by 5.3% in Q2 2026, buying an estimated $314K and bringing the position to 115,020 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #908.

Vanguard Asset Management first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 326 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Vanguard Asset Management held 115,020 shares of Vaxcyte worth $6.69M as of Q2 2026.
  • Vanguard Asset Management bought 5,777 Vaxcyte shares in Q2 2026, an estimated $314K.
  • Vaxcyte made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #908 holding.
  • Vanguard Asset Management first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • 326 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.